Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-01-03
1997-06-17
Kumar, Shailendra
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
549 35, 549 39, A61K 31385, C07D33906
Patent
active
056397828
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND OF THE INVENTION
This application is a 371 of PCT/US92/01830 filed Mar. 4, 1992.
1. Field of the Invention
The present invention is generally related to neolignan derivatives which inhibit both platelet activating factor and 5-lipoxygenase for the treatment of inflammatory and allergic disorders.
2. Description of the Prior Art
Platelet activating factor (PAF) is a highly potent ether linked phospholipid (1-O-alkyl-2-acetyl-sn-glycerol-3-phosphorylcholine) which activates platelets as well as modulates the function of leukocytes and other target cells. PAF has been shown to be a mediator of a variety of pathophysiological conditions including arthritis, acute inflamation, asthma, endotoxic shock, pain, psoriasis, ophthalmic inflammation, ischemia, and gastrointestinal ulceration. Interaction with a specific membrane recognition site coupled to phosphatidylinositol metabolism produces the biological activity of PAF. Hence, blocking the PAF receptor can provide beneficial medical results in human beings and mammals suffering from diseases or disorders mediated by PAF.
Several PAF antagonists have recently been synthesized or isolated from natural sources. For example, Shen et al. in Proc. Natl. Acad. Sci. (U.S.A.), 82. 672-678 (1985), reported that kadsurenone, a neolignan derivative isolated from Piper fotukadsura Sieb et Zucc (a Chinese herbal plant), was a potent, specific and competitive inhibitor of PAF at the receptor level. Biftu et al., in J. Med. Chem. 29, 1917 (1986), and Ponpipom et al., in Biochem. Bioshys. Res. Comm. 150, 1213 (1988), have shown that 2,5-diaryltetrahydrofurans L-652,731 and L-659,989 (both of which are synthetic analogs of neolignan), respectively, are potent PAF receptor antagonists. U.S. Pat. No. 4,539,332 to Biftu et al. and U.S. Pat. No. 4,595,693 to Biftu et al. are both related to the use of 2,5-diaryltetrahydrofurans and their analogs as PAF antagonists. Graham et al., in 197th Amer. Chem. Soc. National Meeting Abstracts, 1989, MEDI, 25, 20, Corey, et al. in Tet. Lett., Vol. 29, 2899-2902 (1988), and U.S. Pat. No. 4,656,190 to Shen et al. respectively show that 1,3-diarylcyclopentanes, 2,4-diaryldioxolanes, and indene derivatives are also potent PAF receptor antagonists.
Leukotrienes, lke PAF, are potent lipid mediators of a variety of topical and systemic diseases and disorders. 5-lipoxygenase catalyzes the conversion of arachidonic acid to leukotriene A4 which is the precursor of leukotrienes B4 and C4. Leukotrienes B4 and C4 are oxygenated metabolites that contribute to the pathogenesis of such inflammatory disorders as arthritis, asthma, psoriasis, and thrombotic disease. Leukotrienes are released concomitantly from leukocytes with PAF from a common phospholipid precursor upon cellular activation and act synergistically with PAF in many biological models. It has been demonstrated that a physical combination of a PAF antagonist and a leukotriene inhibitor is significantly more effective than either agent alone in treating asthma in an animal model (see, O'Donnell et al. in Therapeutic Approaches to inflammatory Diseases, Lewis et al., Elsevier, New York, 1989, pp.169-193).
Shen et al., in PAF and Related Lipid Mediators, Plenum Pub., New York, 164 (1987) and Page et al., in Trends in Pharmacol. Sci. 10, 1 (1989), pointed out that single compounds which posess the dual inhibitory capability of PAF and leukotriene inhibition would have greater antiinflammatory activities than a physical combination of a PAF and a leukotriene inhibitor. Moreover, the chemical combination of PAF and 5-lipoxygenase inhibitory activities in one molecule has advantages over drug combinations in terms of optimal pharmacokinetics, clinical applications and developmental costs. However, few compounds are known which posess this dual inhibitory activity. Shen et al., in PAF and Related Lipid Mediators, Plenum Pub: New York, 153-190 (1987), reported that a tetrahydrothiophene analog of lignan, L-653,150, is both a potent PAF antagonists and a moderate inhibitor of 5-lipoxygenase. Europ
REFERENCES:
patent: 2690988 (1954-10-01), Jones et al.
patent: 4166452 (1979-09-01), Generales, Jr.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4522811 (1985-06-01), Eppstein et al.
patent: 4539332 (1985-09-01), Biftu et al.
patent: 4595693 (1986-06-01), Biftu et al.
patent: 4604407 (1986-08-01), Haslanger et al.
patent: 4656190 (1987-04-01), Shen et al.
patent: 4757084 (1988-07-01), Biftu et al.
patent: 4841968 (1989-06-01), Dunn et al.
patent: 4845129 (1989-07-01), Anderson et al.
patent: 4871756 (1989-10-01), Gillard et al.
patent: 4873259 (1989-10-01), Summers, Jr., et al.
patent: 4876346 (1989-10-01), Musser et al.
patent: 4891363 (1990-01-01), Nakamura et al.
patent: 4910206 (1990-03-01), Houlihan
patent: 4916145 (1990-04-01), Tilley et al.
patent: 4959361 (1990-09-01), Walser
patent: 4987132 (1991-01-01), Mase et al.
patent: 4992428 (1991-02-01), Houlihan et al.
patent: 4996203 (1991-02-01), Biftu et al.
patent: 5001123 (1991-03-01), Biftu et al.
patent: 5037853 (1991-08-01), Brooks et al.
patent: 5110831 (1992-05-01), Magolda et al.
patent: 5112848 (1992-05-01), Brooks et al.
patent: 5169854 (1992-12-01), Brooks et al.
patent: 5175183 (1992-12-01), Brooks et al.
patent: 5183818 (1993-02-01), Brooks et al.
patent: 5187192 (1993-02-01), Brooks et al.
patent: 5234950 (1993-08-01), Edwards et al.
patent: 5244896 (1993-09-01), Borcherding et al.
patent: 5288751 (1994-02-01), Brooks et al.
patent: 5326787 (1994-07-01), Brooks et al.
patent: 5334616 (1994-08-01), Brooks et al.
patent: 5358938 (1994-10-01), Cai et al.
patent: 5420164 (1995-05-01), Mishina et al.
patent: 5434151 (1995-07-01), Cai et al.
Bartroli, J., "Design of Potent Linear PAF Antagonist," J. Med. Chem., vol. 34 (1991) pp. 3328-3334.
Biftu, T., et al., "Conformation and Activity of Tetraydrofuran Lignans and Analogues as Specific Platelet Activating Factor Antagonists," J. Med. Chem. vol. 29, No. 10 (1986) pp. 1917-1921.
Carlcellar, E., et al., "4-Substituted 2-Alkoxytetrahydrofurans as Potent and Long-Lasting PAF Antagonists," J. Med. Chem., vol. 35 (1992) pp. 676-683.
Corey, F.J. et al., "Dual Binding Modes to the Receptor for Platelet Activating Factor (PAF) of Anti-PAF Trans-2,5-Diarylfurans," Tetrahedron Letters, vol. 29, No. 24 (1988) pp. 2899-2902.
Crawley, G.C., "Methoxytetrahydropyrans. A New Series of Selective and Orally Potent 5-Lipoxygenase Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2600-2609.
Feinmark, S. J., "Leukotriene C.sub.4 Biosynthesis during Polymorphonuclear Leukocyte-Vascular Cell Interactions," Methods in Enzmology, vol. 187, pp. 559-560 1992.
Guthrie, R.W., et al., "Propenyl Carboxamide Derivatives As Antagonists of Platelet Activating Factor," J. Med. Chem., vol. 33 (1990) pp. 2856-2864.
Graham, D.W., et al., "1,3-Diarylcyclopentanes: A New Class of Potent PAF Receptor Antagonists," MEDI 1990.
Hwang, S., "Specific Receptors of Platelet-Activating Factor, Receptor Heterogeneity, and Signal Transduction Mechanisms," J. Lipid Mediators, vol. 2 (1990) pp. 123-158.
Lave, D., et al., "Pyrrolo[1,2-c]Thiazole Derivatives: Potent PAF Receptor Antagonists," Drugs of the Future, vol. 14, No. 9 (1989) pp. 891-898.
McColl, S.R., "Determination of 5-Lipoxygenase Activity in Human Polymorphonuclear Leukocytes Using High-Performance Liquid Chromatography," J. Chromatography, vol. 378 (1986) pp. 44-449.
Musser, J.H., et al., "5-Lipoxygenase: Properties, Pharmacology, and the Quinolinyl(bridge)aryl Class of Inhibitors," J. Med. Chem., vol. 35, No. 14 (1992) pp. 2502-2524.
Goldstein, D., et al., "Dual Inhibitors of Platelet Activating Factor and 5-Lipoxygenase II . . . " Chemical Abstracts vol. 118, No. 19, May 1993, Abstract No. 185258m.
Goldstein, D., et al., "Dual Inhibitors of Platelet Activating Factor and 5-Lipoxygenase I.," Chemical Abstracts, vol. 118, No. 19, May 1993, Abstract No. 182990h.
O'Donnell, M., et al., "Comparison of the Pulmonary Pharmacology of Leukotrienes and PAF: Effects of their Antagonists," Ther
Gingrich Diane M.
Goldstein David
Shen T. Y.
Cebulak Mary C.
Center For Innovative Technology
Knowles Sherry M.
Kumar Shailendra
LandOfFree
Neolignan derivatives as platelet activating factor receptor ant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neolignan derivatives as platelet activating factor receptor ant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neolignan derivatives as platelet activating factor receptor ant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2158218